Fallopian Tube Cancer - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 677 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2016, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.

Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Unknown stages are 1, 2, 12, 51, 25, 1, 1, 8 and 1 respectively for Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 3 and 1 molecules, respectively for Fallopian Tube Cancer.

Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 6
Fallopian Tube Cancer Overview 7
Therapeutics Development 8
Fallopian Tube Cancer - Therapeutics under Development by Companies 10
Fallopian Tube Cancer - Therapeutics under Investigation by Universities/Institutes 16
Fallopian Tube Cancer - Pipeline Products Glance 17
Fallopian Tube Cancer - Products under Development by Companies 21
Fallopian Tube Cancer - Products under Investigation by Universities/Institutes 27
Fallopian Tube Cancer - Companies Involved in Therapeutics Development 28
Fallopian Tube Cancer - Therapeutics Assessment 106
Drug Profiles 133
Fallopian Tube Cancer - Discontinued Products 657
Fallopian Tube Cancer - Product Development Milestones 658
Appendix 664

List of Tables

Number of Products under Development for Fallopian Tube Cancer, H2 2016 20
Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H2 2016 21
Number of Products under Development by Companies, H2 2016 23
Number of Products under Development by Companies, H2 2016 (Contd..1) 24
Number of Products under Development by Companies, H2 2016 (Contd..2) 25
Number of Products under Development by Companies, H2 2016 (Contd..3) 26
Number of Products under Development by Companies, H2 2016 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H2 2016 28
Comparative Analysis by Late Stage Development, H2 2016 29
Comparative Analysis by Clinical Stage Development, H2 2016 30
Comparative Analysis by Early Stage Development, H2 2016 31
Comparative Analysis by Unknown Stage Development, H2 2016 32
Products under Development by Companies, H2 2016 33
Products under Development by Companies, H2 2016 (Contd..1) 34
Products under Development by Companies, H2 2016 (Contd..2) 35
Products under Development by Companies, H2 2016 (Contd..3) 36
Products under Development by Companies, H2 2016 (Contd..4) 37
Products under Development by Companies, H2 2016 (Contd..5) 38
Products under Investigation by Universities/Institutes, H2 2016 39
Fallopian Tube Cancer - Pipeline by AbbVie Inc, H2 2016 40
Fallopian Tube Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 41
Fallopian Tube Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 42
Fallopian Tube Cancer - Pipeline by Aduro BioTech, Inc., H2 2016 43
Fallopian Tube Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016 44
Fallopian Tube Cancer - Pipeline by Amgen Inc., H2 2016 45
Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2016 46
Fallopian Tube Cancer - Pipeline by AstraZeneca Plc, H2 2016 47
Fallopian Tube Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016 48
Fallopian Tube Cancer - Pipeline by Bayer AG, H2 2016 49
Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 50
Fallopian Tube Cancer - Pipeline by Boston Biomedical, Inc., H2 2016 51
Fallopian Tube Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016 52
Fallopian Tube Cancer - Pipeline by Celsion Corporation, H2 2016 53
Fallopian Tube Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016 54
Fallopian Tube Cancer - Pipeline by Clovis Oncology, Inc., H2 2016 55
Fallopian Tube Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2016 56
Fallopian Tube Cancer - Pipeline by CTI BioPharma Corp., H2 2016 57
Fallopian Tube Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 58
Fallopian Tube Cancer - Pipeline by EirGenix Inc., H2 2016 59
Fallopian Tube Cancer - Pipeline by Eisai Co., Ltd., H2 2016 60
Fallopian Tube Cancer - Pipeline by Eli Lilly and Company, H2 2016 61
Fallopian Tube Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 62
Fallopian Tube Cancer - Pipeline by Exelixis, Inc., H2 2016 63
Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 64
Fallopian Tube Cancer - Pipeline by Galena Biopharma, Inc., H2 2016 65
Fallopian Tube Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2016 66
Fallopian Tube Cancer - Pipeline by Gene Techno Science Co., Ltd., H2 2016 67
Fallopian Tube Cancer - Pipeline by Genentech, Inc., H2 2016 68
Fallopian Tube Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 69
Fallopian Tube Cancer - Pipeline by Glycotope GmbH, H2 2016 70
Fallopian Tube Cancer - Pipeline by Gradalis Inc., H2 2016 71
Fallopian Tube Cancer - Pipeline by Ignyta, Inc., H2 2016 72
Fallopian Tube Cancer - Pipeline by Immune Design Corp., H2 2016 73
Fallopian Tube Cancer - Pipeline by ImmunoGen, Inc., H2 2016 74
Fallopian Tube Cancer - Pipeline by Immunovaccine, Inc., H2 2016 75
Fallopian Tube Cancer - Pipeline by Incyte Corporation, H2 2016 76
Fallopian Tube Cancer - Pipeline by Innate Pharma S.A., H2 2016 77
Fallopian Tube Cancer - Pipeline by Johnson & Johnson, H2 2016 78
Fallopian Tube Cancer - Pipeline by Juno Therapeutics Inc., H2 2016 79
Fallopian Tube Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 80
Fallopian Tube Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 81
Fallopian Tube Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 82
Fallopian Tube Cancer - Pipeline by Mabion SA, H2 2016 83
Fallopian Tube Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016 84
Fallopian Tube Cancer - Pipeline by Mateon Therapeutics Inc, H2 2016 85
Fallopian Tube Cancer - Pipeline by MedImmune, LLC, H2 2016 86
Fallopian Tube Cancer - Pipeline by Medivation, Inc., H2 2016 87
Fallopian Tube Cancer - Pipeline by Merck & Co., Inc., H2 2016 88
Fallopian Tube Cancer - Pipeline by Merck KGaA, H2 2016 89
Fallopian Tube Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 90
Fallopian Tube Cancer - Pipeline by MolMed S.p.A., H2 2016 91
Fallopian Tube Cancer - Pipeline by Mycenax Biotech Inc., H2 2016 92
Fallopian Tube Cancer - Pipeline by Novartis AG, H2 2016 93
Fallopian Tube Cancer - Pipeline by OBI Pharma, Inc., H2 2016 94
Fallopian Tube Cancer - Pipeline by Oncobiologics, Inc., H2 2016 95
Fallopian Tube Cancer - Pipeline by Oncolix, Inc., H2 2016 96
Fallopian Tube Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016 97
Fallopian Tube Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 98
Fallopian Tube Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 99
Fallopian Tube Cancer - Pipeline by Oxford BioMedica Plc, H2 2016 100
Fallopian Tube Cancer - Pipeline by Pharma Mar, S.A., H2 2016 101
Fallopian Tube Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2016 102
Fallopian Tube Cancer - Pipeline by Quest PharmaTech Inc., H2 2016 103
Fallopian Tube Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016 104
Fallopian Tube Cancer - Pipeline by Samyang Holdings Corporation, H2 2016 105
Fallopian Tube Cancer - Pipeline by Sanofi Pasteur SA, H2 2016 106
Fallopian Tube Cancer - Pipeline by Sellas Inc, H2 2016 107
Fallopian Tube Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016 108
Fallopian Tube Cancer - Pipeline by Sotio a.s., H2 2016 109
Fallopian Tube Cancer - Pipeline by TapImmune Inc., H2 2016 110
Fallopian Tube Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 111
Fallopian Tube Cancer - Pipeline by Tesaro, Inc., H2 2016 112
Fallopian Tube Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2016 113
Fallopian Tube Cancer - Pipeline by Tyrogenex, Inc., H2 2016 114
Fallopian Tube Cancer - Pipeline by Vascular Biogenics Ltd., H2 2016 115
Fallopian Tube Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 116
Fallopian Tube Cancer - Pipeline by Vyriad Inc, H2 2016 117
Assessment by Monotherapy Products, H2 2016 118
Number of Products by Stage and Target, H2 2016 120
Number of Products by Stage and Mechanism of Action, H2 2016 131
Number of Products by Stage and Route of Administration, H2 2016 142
Number of Products by Stage and Molecule Type, H2 2016 144
Fallopian Tube Cancer - Dormant Projects, H2 2016 665
Fallopian Tube Cancer - Dormant Projects (Contd..1), H2 2016 666
Fallopian Tube Cancer - Dormant Projects (Contd..2), H2 2016 667
Fallopian Tube Cancer - Dormant Projects (Contd..3), H2 2016 668
Fallopian Tube Cancer - Discontinued Products, H2 2016 669